Digestive and Liver Disease
Volume 42, Issue 7 , Pages 490-495 , July 2010

Descriptive epidemiology of cholangiocarcinoma in Italy

  • Domenico Alvaro

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, Polo Pontino, Sapienza University of Rome, Rome, Italy
    • Corresponding Author InformationCorresponding author at: Università degli Studi di Roma “Sapienza”, Via Roberto Rossellini 51, 00137 Rome, Italy. Tel.: +39 06 49972023; fax: +39 06 4453319.
    • ,
  • Emanuele Crocetti

      Affiliations

    • Tuscany Cancer Registry, Istituto per lo Studio e la Prevenzione Oncologica, Florence, Italy
    • ,
  • Stefano Ferretti

      Affiliations

    • Ferrara Cancer Registry, University of Ferrara, Italy
    • ,
  • Maria Consiglia Bragazzi

      Affiliations

    • Department of Clinical Medicine, Division of Gastroenterology, Polo Pontino, Sapienza University of Rome, Rome, Italy
    • ,
  • Riccardo Capocaccia

      Affiliations

    • Cancer Epidemiology Unit, National Center for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanità, Rome, Italy
    • ,
  • the AISF “Cholangiocarcinoma” committee

      Affiliations

    • Composition of the AISF (Italian Association for the Study of Liver Disease) “Cholangiocarcinoma” committee: Alvaro Domenico (Coordinator), Benedetti Antonio, Bragazzi Maria Consiglia, Capocaccia Riccardo, Crocetti Emanuele, Fabris Luca, Gianmarco Fava, Ferretti Stefano, Floreani AnnaRosa, Grazi Gianluca, Invernizzi Pietro, Laghi Andrea, Mancino MariaGrazia, Marzioni Marco, Mutignani Massimiliano, Paolantonio Pasquale, Sonzogni Aurelio, Strazzabosco Mario, Stroffolini Tommaso.

Received 22 September 2009 ,Accepted 28 October 2009.

References 

  1. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008;48:308–321
  2. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12:131–150
  3. Khan SA, Miras A, Pelling M, et al. Cholangiocarcinoma and its management. Gut. 2007;56:1755–1756
  4. Patel T, Singh P. Cholangiocarcinoma: emerging approaches to a challenging cancer. Curr Opin Gastroenterol. 2007;23:317–323
  5. Yachimski P, Pratt DS. Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol. 2008;42:178–190
  6. Alvaro D, Mancino MG. New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med. 2008;29:50–57
  7. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology. 2007;132:415–431
  8. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol. 2002;37:1205–1211
  9. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol. 2004;99:523–526
  10. Kaczynski J, Hansson G, Wallerstedt S. Incidence, etiologic aspects and clinicopathologic features in intrahepatic cholangiocellular carcinoma—a study of 51 cases from a low-endemicity area. Acta Oncol. 1998;37:77–83
  11. Pardi DS. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889–893
  12. Stiehl A. Development of dominant bile duct stenoses in patient with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol. 2002;36:151–156
  13. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized controlled study. Gastroenterology. 2005;129:1464–1472
  14. Brandsaeter B, Isoniemi H, Broomé U, et al. Liver transplantation for primary slerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol. 2004;40:815–822
  15. Parkin DM, Srivatanakul P, Khlat M, et al. Liver cancer in Thailand. I. A case control study of cholangicarcinoma. Int J Cancer. 1991;48:323–328
  16. Hansel DE, Rahman A, Hidalgo M, et al. Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol. 2003;163:217–229
  17. Obama K, Ura K, Li M, et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology. 2005;41:1339–1348
  18. Jinawath N, Chamgramol Y, Furukawa Y, et al. Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. J Hepatol. 2006;44:1025–1038
  19. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–1357
  20. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15:1198–1203
  21. Welzel TM, McGlynn KA, Hsing AW, et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98:873–875
  22. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol. 2004;40:472–477
  23. Wood R, Brewster DH, Fraser LA, et al. Do increases in mortality from intrahepatic cholangiocarcinoma reflect a genuine increase in risk? Insights from cancer registry data in Scotland. Eur J Cancer. 2003;39:2087–2092
  24. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2002;3:10
  25. West J, Wood H, Logan RF, et al. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer. 2006;94:1751–1758
  26. www.rarecare.eu
  27. Jepsen P, Vilstrup H, Tarone RE, et al. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst. 2007;99:895–897
  28. Alvaro D, Macarri G, Mancino MG, et al. Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis. Ann Intern Med. 2007;147:451–459
  29. Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–284
  30. El-Serag HB, Engels EA, Landgren O, et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology. 2009;49:116–123
  31. Lee TY, Lee SS, Jung SW, et al. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol. 2008;103:1716–1720
  32. Höblinger A, Lammert F. Genetics of biliary tract diseases: new insights into gallstone disease and biliary tract cancers. Curr Opin Gastroenterol. 2008;24:363–371

PII: S1590-8658(09)00433-2

doi: 10.1016/j.dld.2009.10.009

Digestive and Liver Disease
Volume 42, Issue 7 , Pages 490-495 , July 2010

Article Tools

* Image Usage & Resolution